Closed call · historical reference
Specific Challenge:Vaccines and monoclonal Antibodies (mAb) may reduce antimicrobial resistance (AMR). However, individual vaccine developers and manufacturers, as well as organisations developing mAbs and health authorities, acting alone, do not have the resources and the full expertise required t…
Topics
Partner types
clinical_research_consortium, healthcare_provider, research_institution, university
